116986-13-1

Basic information

• Product Name: 3-BROMOMETHYL-PYRIDINE-2-CARBONITRILE
• Synonyms: 3-BROMOMETHYL-PYRIDINE-2-CARBONITRILE;3-BroMoMethyl-2-cyanopyridine, 97%;3-(broMoMethyl)picolinonitrile;3-(bromomethyl)-2-Pyridinecarbonitrile
• CAS NO: 116986-13-1
• Molecular Formula: C₇H₅BrN₂
• Molecular Weight: 197.032
• Product Categories: Pyridine series;Methyl Halides;Pyridines;Methyl Halides
• Mol File: 116986-13-1.mol

Chemical Properties

• Boiling Point: 308.2 °C at 760 mmHg
• Flash Point: 140.2 °C
• Appearance: /
• Density: 1.6 g/cm³
• Vapor Pressure: 0.00069mmHg at 25°C
• Refractive Index: 1.591
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.23±0.10(Predicted)
• CAS DataBase Reference: 3-BROMOMETHYL-PYRIDINE-2-CARBONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMOMETHYL-PYRIDINE-2-CARBONITRILE(116986-13-1)
• EPA Substance Registry System: 3-BROMOMETHYL-PYRIDINE-2-CARBONITRILE(116986-13-1)

Safety Data

• RIDADR: UN3439
• Hazardous Substances Data: 116986-13-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromomethyl-pyridine-2-carbonitrile is used as a key intermediate for the synthesis of various drug candidates and APIs. Its reactivity and versatility make it an essential component in the development of new pharmaceuticals, contributing to the advancement of medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Bromomethyl-pyridine-2-carbonitrile is utilized as a building block in the production of fungicides, herbicides, and insecticides. Its role in these applications is to provide a foundation for the creation of effective and targeted agrochemicals that protect crops and manage pests.
Used in Organic Synthesis and Drug Discovery Research:
3-Bromomethyl-pyridine-2-carbonitrile is employed as a highly reactive and versatile chemical in organic synthesis and drug discovery research. Its properties allow researchers to explore new chemical pathways and develop innovative compounds with potential therapeutic or agricultural applications.

InChI:InChI=1/C7H5BrN2/c8-4-6-2-1-3-10-7(6)5-9/h1-3H,4H2

Upstream product

• 20970-75-6 2-cyano-3-methylpyridine 

Downstream Products

• 81109-81-1 2-cyano-3-(phenylthiomethyl)pyridine 
• 131747-56-3 3-(hydroxymethyl)pyridine-2-carbonitrile 
• 55942-66-0 3-(phenoxymethyl)pyridine-2-carboxylic acid 
• 55942-67-1 3-(phenylthiomethyl)pyridine-2-carboxylic acid 
• 126570-66-9 3-[(3-chlorophenyl)thiomethyl]-2-cyanopyridine 
• 916800-04-9 3-((2,6-dichlorophenoxy)methyl)-2-picolinenitrile 
• 5912-34-5 2-cyano-pyridin-3-yl-acetonitrile 
• 1201843-32-4 N-(2-chloro-5-(1,7-naphthyridin-6-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide 
• 5912-36-7 1,7-naphthyridin-6-amine 
• 5912-35-6 8-bromo-[1,7]naphthyridin-6-ylamine 
• 1324006-68-9 7-aza-5,6-dihydro-2,3-dimethoxy-5-oxo-11H-indeno[1,2-c]isoquinoline 

Relevant articles and documents

Synthesis and properties of a novel Cu(II)-pyridineoxazoline containing polymeric catalyst for asymmetric Diels-Alder reaction

A novel pyridineoxazoline (PyOx) containing optically active polymer, poly[(-)-(S)-4-tert-butyl-2-(3-vinylpyridin-2-yl)-oxazoline], was prepared via the radical polymerization of (-)-(S)-4-tert-butyl-2-(3-vinylpyridin-2-yl)-oxazoline. Its complex with Cu(OTf)2 was employed to catalyse the homogeneous Diels-Alder (D-A) reaction of 2-alkenoyl pyridine N-oxide and cyclopentadiene in tetrahydrofuran. The polymeric catalyst showed a 5 fold faster reaction rate and a 2.5 fold higher enantio-selectivity than the Cu(II) complex of (-)-(S)-4-tert-butyl-2-(3-methylpyridin-2-yl)-oxazoline, a low molecular mass model compound. This was rationalized by the constrained environment around catalytic site provided by the polymer backbone in terms of CD spectrometry results. The polymer complex was easily recycled by the precipitation method, and only a slight decrease of reactivity and enantio-selectivity was observed after 5 cycles.

METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS

The subject matter described herein is directed to ferroportin inhibitor compounds of Formula (I) and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.

ETHER LINKED TRIAZOLES AS NRF2 REGULATORS

The present invention relates to ether-linked triazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof:

Modular Route to Azaindanes

A convergent radical based route to azaindanes is described, relying on the degenerative addition transfer of various substituted S-(pyridylmethyl)-O-ethyl dithiocarbonates (xanthates) to functional alkenes followed by radical cyclization onto the pyridine ring activated by protonation with trifluoroacetic acid. In one case, a richly decorated cyclohepta[b]pyridine could be assembled swiftly by allowing the first adduct to N-phenylmaleimide to undergo addition to N-allylphthalimide prior to cyclization.

THERAPEUTIC INHIBITORY COMPOUNDS

The invention provides compounds of Formula I and Formula II: A-B-C-D-E-F-G-J (I) C-D-E-F-G-J (II) wherein A, B, C, D, E, F, G, and J have any of the values defined in the specification, and salts thereof. The compounds are useful for inhibiting plasma kallikrein, and for treating a disease or condition in an animal where inhibition of plasma kallikrein is indicated.

AZAINDENOISOQUINOLINE TOPOISOMERASE I INHIBITORS

The invention described herein pertains to substituted azaindenoisoquinoline compounds, in particular 7-, 8-, 9-, and 10-azaindenoisoquinoline compounds, which are inhibitors of topoisomerase I, processes and intermediates for their syntheses, pharmaceutical compositions of the compounds, and methods of using them in the treatment of cancer.

SELECTIVE CYP11B1 INHIBITORS FOR THE TREATMENT OF CORTISOL DEPENDENT DISEASES

The present invention relates to compounds which selectively inhibit CYP11B1. Preferably, the compounds of the present invention do not substantially inhibit CYP11B2. Moreover, the compounds of the present invention do not substantially inhibit CYP17 and/or CYP19, either. Amongst other applications of the compounds of the present invention, they can be used for the treatment of Cushing's syndrome or metabolic disease.

Phospshoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: Discovery and structure-activity relationships of a series of quinoline and quinoxaline derivatives

The phosphoinositide 3-kinase (PI3K) family catalyzes the ATP-dependent phosphorylation of the 3′-hydroxyl group of phosphatidylinositols and plays an important role in cell growth and survival. There is abundant evidence demonstrating that PI3K signaling is dysregulated in many human cancers, suggesting that therapeutics targeting the PI3K pathway may have utility for the treatment of cancer. Our efforts to identify potent, efficacious, and orally available PI3K/mammalian target of rapamycin (mTOR) dual inhibitors resulted in the discovery of a series of substituted quinolines and quinoxalines derivatives. In this report, we describe the structure-activity relationships, selectivity, and pharmacokinetic data of this series and illustrate the in vivo pharmacodynamic and efficacy data for a representative compound.

Optimization of the first selective steroid-11β-hydroxylase (CYP11B1) inhibitors for the treatment of cortisol dependent diseases

CYP11B1 is the key enzyme in cortisol biosynthesis, and its inhibition with selective compounds is a promising strategy for the treatment of diseases associated with elevated cortisol levels, such as Cushing's syndrome or metabolic disease. Expanding on a

Synthesis and SAR of novel CXCR4 antagonists that are potent inhibitors of T tropic (X4) HIV-1 replication

An early lead from the AMD070 program was optimized and a structure-activity relationship was developed for a novel series of heterocyclic containing compounds. Potent CXCR4 antagonists were identified based on anti-HIV-1 activity and Ca2+ flux